Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; CANCER ; GROWTH ; GROWTH-FACTOR ; proliferation ; tumor ; CELL-PROLIFERATION ; PATHWAY ; RISK ; GENE ; GENES ; PROTEIN ; TUMORS ; RELEASE ; PATIENT ; BINDING ; ASSOCIATION ; polymorphism ; POLYMORPHISMS ; single nucleotide polymorphism ; VARIANTS ; BREAST ; breast cancer ; BREAST-CANCER ; hormone ; COLORECTAL-CANCER ; PROSTATE-CANCER ; cancer risk ; case-control studies ; SOMATOSTATIN ; CANCER PATIENTS ; nutrition ; FACTOR-I ; BINDING PROTEIN ; SERUM ; SINGLE ; IGF-I ; BINDING-PROTEIN ; case-control study ; ASSOCIATIONS ; RE ; VARIANT ; SINGLE NUCLEOTIDE POLYMORPHISMS ; cell proliferation ; development ; GROWTH-FACTOR-I ; BINDING PROTEIN-3 ; LEVEL ; case control studies ; GENOTYPE DATA ; FACTOR (IGF)-I ; PREMENOPAUSAL WOMEN ; IGFBP3 ; insulin-like growth factor ; PLASMA-LEVELS ; SERUM-LEVELS
    Abstract: Insulin-like growth factor-I (IGF-I) stimulates cell proliferation and can enhance the development of tumors in different organs. Epidemiologic studies have shown that an elevated level of circulating IGF-I is associated to increased risk of breast cancer as well as other cancers. Genetic variants affecting the release or biological action of growth hormone (GH), the main stimulator of IGF-I production, may predict circulating levels of IGF-I and have an effect on cancer risk. We tested this hypothesis with a large case-control study of 807 breast cancer patients and 1,588 matched control subjects nested within the European Prospective Investigation into Cancer and Nutrition. We genotyped 22 common single nucleotide polymorphisms in 10 genes involved in GH production and action (GHRH, GHRHR, SST, SSTR1-SSTR5, POU1F1, and GH1), and in parallel, we measured serum levels of IGF-I and IGFBP-3, its major binding protein, in samples of cases and controls. SST and SSTR2 polymorphisms showed weak but statistically significant associations with breast cancer risk. SSTR5 polymorphisms were associated with IGF-I levels, whereas one polymorphism in GHRHR and one in POU1F1 were associated with IGFBP-3 levels. Our conclusion is that common genetic variation in the GH synthesis pathway, as measured by single nucleotide polymorphisms selected in the present study, is not a major determinant of IGF-I and IGFBP-3 circulating levels, and it does not play a major role in altering breast cancer risk
    Type of Publication: Journal article published
    PubMed ID: 16214911
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: APOPTOSIS ; CANCER ; GROWTH ; proliferation ; COHORT ; RISK ; GENE ; polymorphism ; POLYMORPHISMS ; single nucleotide polymorphism ; BREAST-CANCER ; prostate cancer ; SNPs ; GROWTH-FACTOR-I ; HAPLOTYPE ; TWINS ; CIRCULATING LEVELS ; IGFBP-3 ; REPEAT ; block ; IGF1 ; BINDING PROTEIN-1
    Abstract: Insulin-like growth factor-I (IGF1) stimulates cell proliferation, decreases apoptosis, and has been implicated in cancer development. Epidemiological studies have shown elevated levels of circulating IGF1 to be associated with increased risk of prostate cancer. To what extent genetic variation in the IGF1 gene is related to prostate cancer risk is largely unknown. We performed a comprehensive haplotype tagging (HT) assessment of single nucleotide polymorphisms (SNPs) representing the common haplotype variation in the IGF1 gene. We genotyped 10 SNPs (9 haplotype tagging SNPs (htSNPs)) within Cancer Prostate in Sweden (CAPS), a case-control study of 2,863 cases and 1,737 controls, in order to investigate if genetic variation in the IGF1 gene is associated with prostate cancer risk. Three haplotype blocks were identified across the IGF1 gene and 9 SNPs were selected as haplotype tagging SNPs. Common haplotypes in the block covering the 3' region of the IGF1 gene showed significant global association with prostate cancer risk (p = 0.004), with one particular haplotype giving an odds ratio of 1.46 (95% CI = 1.15-1.84, p = 0.002). This haplotype had a prevalence of 5% in the study population. Our results indicate that common variation in the IGF1 gene, particularly in the 3' region, mail affect prostate cancer risk. Further studies on genetic variations in the IGF1 gene in relation to prostate cancer risk as well as to circulating levels of IGF1 are needed to confirm this novel finding. (c) 2006 Wiley-Liss. Inc
    Type of Publication: Journal article published
    PubMed ID: 17096324
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: RECEPTOR ; CANCER ; GROWTH ; GROWTH-FACTOR ; Germany ; DIAGNOSIS ; RISK ; GENE ; GENOME ; TIME ; LINKAGE ; SUSCEPTIBILITY ; hormone ; DISRUPTION ; etiology ; MEN ; prostate cancer ; PROSTATE-CANCER ; SWEDEN ; cancer risk ; case-control studies ; FACTOR-I ; case-control study ; RE ; FAMILIES ; GROWTH-FACTOR-I ; ELDERLY-MEN ; I IGF-I ; case control studies ; INTERVAL ; analysis ; HAPLOTYPE ; odds ratio ; CANCER-RISK ; CIRCULATING LEVELS ; MULTIETHNIC COHORT ; retrospective ; Insulin-Like Growth Factor I ; BODY-MASS-INDEX ; BINDING PROTEIN-1 ; DIET-INDUCED OBESITY
    Abstract: The growth hormone receptor (GHR) is potentially involved in prostate cancer through its role in stimulating insulin-like growth factor I production and its cellular effects on prostate epithelium. We have used a haplotype-based tagging approach within CAncer Prostate Sweden, a large retrospective case-control study of 2,863 cases and 1,737 controls to investigate if genetic variation in the GHR gene influences prostate cancer risk. One haplotype in the 3' region of the GHR gene was found associated with prostate cancer risk in elderly men (〉 65 years old at the time of diagnosis), with heterozygote haplotype carriers having an odds ratio of 1.65 (95% confidence interval, 1.21-2.16; P = 0.0009, P-corrected = 0.03). GHR function has been implicated in the determination of body mass index. Interestingly, the same haplotype associated with risk in the 3' end of the GHR gene was also associated with a decrease in body mass index in controls (P = 0.003, P-corrected = 0.05), possibly indicating some functionality with this haplotype. These results suggest that whereas genetic variation in the GHR gene does not seem to play a major role in prostate cancer etiology, one haplotype in the 3' region may be potentially relevant to cases with later onset of prostate cancer
    Type of Publication: Journal article published
    PubMed ID: 17220348
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: DISEASE ; HISTORY ; POPULATION ; GENE ; COMPLEX ; COMPLEXES ; FAMILY ; SEQUENCE ; VARIANTS ; AMPLIFICATION ; MUTATION ; DELETIONS ; REGION ; REGIONS ; MUTATIONS ; PHENOTYPE ; FREQUENT ; PREVALENCE ; VARIANT ; LOCUS ; MUTATION ANALYSIS ; PARAPLEGIA ; HEREDITARY ATAXIAS ; PARAPARESIS ; SPG4 GENE
    Abstract: Background: Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous disorder that can be an autosomal-dominant, autosomal-recessive, or X-linked disease. The most common autosomal-dominant form of the disease derives from mutations in the SPAST gene. Methods: The aim of this study was to analyze 49 patients diagnosed with HSP from the Estonian population for sequence variants of the SPAST gene and to describe the associated phenotypes. Healthy control individuals (n = 100) with no family history of HSP were also analyzed. All patient samples were screened using denaturing high performance liquid chromatography (DHPLC) and multiplex ligation-dependent probe amplification (MLPA) assay. Samples with abnormal DHPLC and MLPA profiles were sequenced, with the same regions sequenced in control samples. Results: Sequence variants of SPAST were identified in 19/49 HSP patients (38.8%), twelve among them had pathogenic mutations. Within the latter group there was one sporadic case. Eight patients had pure, and four complex HSP. The twelve variants were identified: seven pathogenic (c.1174-1G〉C, c.1185delA, c.1276C〉T, c.1352_1356delGAGAA, c.1378C〉A, c.1518_1519insTC, c.1841_1842insA) and five non-pathogenic (c.131C〉T, c.484G〉A, c.685A〉G, c.1245+202delG, c.1245+215G〉C). Only 2 of these mutations had previously been described (c.131C〉T, c.1245+202delG). Three mutations, c.1174-1G〉C, c.1276C〉T, c.1378C〉A, showed intrafamilial segregation. Conclusion: This study identified new variants of the SPAST gene which included benign missense variants and short insertions/deletions. No large rearrangements were found. Based on these data, HSP are associated with clinical phenotypes
    Type of Publication: Journal article published
    PubMed ID: 20214791
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: CANCER ; GROWTH ; proliferation ; RISK ; GENE ; GENES ; PROTEIN ; PROTEINS ; PATIENT ; BINDING ; ASSOCIATION ; polymorphism ; POLYMORPHISMS ; BREAST ; breast cancer ; BREAST-CANCER ; WOMEN ; COLORECTAL-CANCER ; PROSTATE-CANCER ; cancer risk ; FACTOR-I ; SERUM ; IGF-I ; RE ; SINGLE NUCLEOTIDE POLYMORPHISMS ; CANDIDATE GENES ; GROWTH-FACTOR-I ; LEVEL ; case control studies ; single-nucleotide ; GENOTYPE DATA ; FACTOR (IGF)-I ; PREMENOPAUSAL WOMEN ; PLASMA-LEVELS ; SERUM-LEVELS ; ALPHA-5-BETA-1 INTEGRIN ; C-PEPTIDE ; IGFALS ; IGFBP-1 ; IGFBP-3 ; MULTIETHNIC COHORT
    Abstract: Insulin-like growth factor I (IGF-1) stimulates cell proliferation and can enhance the development of tumours in different organs. Epidemiological studies have shown that an elevated level of circulating IGF-1 is associated with increased risk of breast cancer, as well as of other cancers. Most of circulating IGF-I is bound to an acid-labile subunit and to one of six insulin-like growth factor binding proteins (IGFBPs), among which the most important are IGFBP-3 and IGFBP-1. Polymorphisms of the IGF1 gene and of genes encoding for the major IGF-1 carriers may predict circulating levels of IGF-1 and have an impact on cancer risk. We tested this hypothesis with a case - control study of 807 breast cancer patients and 1588 matched control subjects, nested within the European Prospective Investigation into Cancer and Nutrition. We genotyped 23 common single nucleotide polymorphisms in IGF1, IGFBP1, IGFBP3 and IGFALS, and measured serum levels of IGF-1 and IGFBP-3 in samples of cases and controls. We found a weak but significant association of polymorphisms at the 50 end of the IGF1 gene with breast cancer risk, particularly among women younger than 55 years, and a strong association of polymorphisms located in the 50 end of IGFBP3 with circulating levels of IGFBP-3, which confirms previous findings. Common genetic variation in these candidate genes does not play a major role in altering breast cancer risk in Caucasians
    Type of Publication: Journal article published
    PubMed ID: 16404426
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: CANCER ; CELLS ; EXPRESSION ; tumor ; Germany ; human ; INHIBITION ; RISK ; GENE ; GENES ; PROTEIN ; SEQUENCE ; SEQUENCES ; FREQUENCY ; polymorphism ; POLYMORPHISMS ; SUSCEPTIBILITY ; VARIANTS ; FREQUENCIES ; ALPHA ; BREAST ; breast cancer ; BREAST-CANCER ; ACID ; HEALTH ; BRCA1 ; WOMEN ; PROSTATE-CANCER ; cancer risk ; case-control studies ; nutrition ; ONCOLOGY ; case-control study ; VARIANT ; BODY-SIZE ; GROWTH-FACTOR-I ; biomarker ; case control studies ; INTERVAL ; ENZYME ; analysis ; GENOTYPE ; HAPLOTYPE ; HAPLOTYPES ; ENERGY-BALANCE ; PREMENOPAUSAL WOMEN ; PREMENOPAUSAL ; prospective ; ALLELE FREQUENCIES ; cancer research ; CANCER-RISK ; ALLELE-FREQUENCY ; breast cancer susceptibility ; NONCARRIERS ; FATTY-ACID SYNTHASE ; CARBOXYLASE-ALPHA ; SYNTHESIS PATHWAY
    Abstract: A key fatty acid synthesis enzyme, acetyl-CoA carboxylase alpha(ACC-alpha), has been shown to be highly expressed in human breast cancer and other tumor types and also to specifically interact with the protein coded by one of two major breast cancer susceptibility genes BRCA1. We used a comprehensive haplotype analysis to examine the contribution of the ACC-alpha common genetic variation (allele frequency 〉 5%) to breast cancer in a case-control study (1,588 cases/2,600 controls) nested within the European Prospective Investigation into Cancer and Nutrition. We identified 21 haplotypetagging polymorphisms efficiently capturing common variation within 325 kb of ACC-alpha and surrounding sequences using genotype data from the HapMap project and our resequencing data. We found an effect on overall risk of breast cancer in homozygous carriers of one common haplotype [odds ratio (OR), 1.74; 95% confidence interval (95% CI), 1.03-2.94]. When the data were subdivided by menopausal status, we found statistical evidence of heterogeneity for two other common haplotypes (P value for heterogeneity = 0.016 and 0.045). In premenopausal women, the carriers of these haplotypes, compared with noncarriers, had an altered risk of breast cancer (OR, 0.70; 95% CI, 0.53-0.92 and OR, 1.35; 95% CI, 1.04-1.76). These findings were not significant after adjustment for multiple testing and therefore should be considered as preliminary and evaluated in larger independent studies. However, they suggest a possible role of the ACC-alpha common sequence variants in susceptibility to breast cancer and encourage studies of other genes involved in fatty acid synthesis
    Type of Publication: Journal article published
    PubMed ID: 17372234
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...